In NSCLC, Longer Survival With Brigatinib Than Crizotinib

MONDAY, Oct. 15, 2018 -- Among patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor, progression-free survival is significantly longer in those who receive...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news